DCM
SRPT icon

Dialectic Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Dialectic Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-78,408
Closed -$4.82M – 102
2016
Q3 		$4.82M Buy
78,408
+48,408
+161% +$1.46M 3% 8
2016
Q2 		$572K Buy
+30,000
New +$556K 0.19% 76

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $494M AUM 23.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dialectic Capital Management's SRPT Position: Q4 2016 in Review

Dialectic Capital Management sold out of Sarepta Therapeutics (SRPT) in Q4 2016, closing a stake of 78,408 shares — an estimated $4.82M sold.

Dialectic Capital Management first reported a position in SRPT in Q2 2016 and held it in 2 quarters. The position peaked at $4.82M in Q3 2016. 178 funds tracked by Wall St. Rank hold SRPT as of Q4 2016.

  • Dialectic Capital Management reported no remaining Sarepta Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Dialectic Capital Management sold 78,408 Sarepta Therapeutics shares in Q4 2016, an estimated $4.82M.
  • Dialectic Capital Management first reported a position in Sarepta Therapeutics in Q2 2016 and held it in 2 quarters.
  • Dialectic Capital Management's Sarepta Therapeutics position peaked at $4.82M in Q3 2016.
  • 178 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2016.

Based on Dialectic Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.